MINI FUTURE LONG - BB BIOTECH N Share Price

Certificat

DE000PR0EU23

Market Closed - Börse Stuttgart 09:37:34 02/05/2024 BST
1.44 EUR +3.60% Intraday chart for MINI FUTURE LONG - BB BIOTECH N
1 month-24.46%
3 months-14.72%
Date Price Change Volume
02/05/24 1.44 +3.60% 0
30/04/24 1.39 +6.11% 0
29/04/24 1.31 0.00% 0
26/04/24 1.31 -2.96% 250
25/04/24 1.35 -2.88% 0

Delayed Quote Börse Stuttgart

Last update May 02, 2024 at 09:37 am

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying BB BIOTECH AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PR0EU2
ISINDE000PR0EU23
Date issued 11/11/2016
Strike 27.86 CHF
Maturity Unlimited
Parity 10 : 1
Emission price 0.82
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 5.45
Lowest since issue 0.6

Company Profile

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Sector
-
More about the company

Ratings for BB Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BB Biotech AG

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
42.2 CHF
Average target price
47.7 CHF
Spread / Average Target
+13.03%
Consensus